Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Seres Therapeutics Q3 2025 Earnings Call - Advancing SER-155 with Key FDA Alignment and Capital Focus
Seres Therapeutics reported a net income of $8.2 million in Q3 2025, driven primarily by a $27.2 million gain on the sale of VAST. The company is focused on advancing SER-155, its lead oral live bioth...
- Seres reported $8.2 million net income in Q3 2025 compared to a $51 million loss a year ago, largely due to a $27.2 million gain from VAST sale installment payment.
- SER-155, the lead investigational oral live biotherapeutic aimed at preventing bloodstream infections in alloHSCT patients, showed a 77% relative risk reduction in bacterial bloodstream infections in phase one B study.
- FDA provided constructive feedback on SER-155’s phase two protocol, aligning on study size, dosing, primary endpoint, and interim analysis plan, with no gating items to start pending funding.
- +7 more takeaways
Orion S.A. Q3 2025 Earnings Call - Navigating Demand Slumps and Structural Cost Cuts Amid Market Malaise
Orion S.A. delivered a Q3 2025 report revealing earnings below expectations, challenged primarily by soft demand in key Western markets and elevated tire imports. Despite higher volumes skewed toward ...
- Orion’s Q3 adjusted EBITDA was about $58 million, below expectations but slightly better than mid-October projections.
- Tire production in key markets is down sharply: about 29% in the U.S. and 20-35% across Europe, pressuring carbon black demand.
- Despite solid tire sell-through, elevated tire imports and surplus inventories are reducing OEM production and hitting premium market demand.
- +12 more takeaways
Gladstone Investment Corporation 2Q 2026 Earnings Call - Solid Portfolio Growth Amidst Competitive M&A Landscape and Navigating Uncertainty
Gladstone Investment reported a strong second quarter of fiscal 2026 with adjusted net investment income (NII) of $0.24 per share, covering monthly distributions and supporting a $1.1 billion portfoli...
- Gladstone Investment's adjusted net investment income was $0.24 per share in 2Q fiscal 2026, sufficient to cover monthly shareholder distributions of $0.08 per share.
- Total assets grew by $90 million quarter-over-quarter to $1.1 billion, driven by one new buyout investment and portfolio appreciation.
- The company invested approximately $130 million in three new portfolio companies in the first half of fiscal 2026, nearing the pace of $221 million invested in full fiscal 2025.
- +13 more takeaways
Teva Pharmaceutical Industries Q3 2025 Earnings Call - Sustained Growth Fueled by Austedo and Innovative Pipeline
Teva Pharmaceutical Industries reported its 11th consecutive quarter of revenue growth, with Q3 2025 revenues reaching $4.5 billion, up 3% year over year. The growth was led by a 33% leap in its innov...
- Teva recorded its 11th consecutive quarter of growth with 3% revenue increase to $4.5 billion in Q3 2025.
- Innovative products surged 33% year over year, surpassing $800 million in quarterly revenues.
- Austedo led the innovation charge, growing 38% to $618 million in the US, exceeding $600 million for the first time.
- +13 more takeaways
Acushnet Holdings Corp. Q3 2025 Earnings Call - Solid Equipment Growth Balanced by Regional Apparel Softness and Rising Tariff Pressures
Acushnet Holdings reported a steady third quarter with a 5% constant currency sales increase to $658 million and a 10% boost in adjusted EBITDA at $119 million. The firm’s equipment segments, especial...
- Acushnet achieved a 5% constant currency increase in Q3 2025 net sales to $658 million and a 10% rise in adjusted EBITDA to $119 million.
- Year-to-date sales rose 4% to $2.08 billion with adjusted EBITDA up 2%, reflecting steady growth amid mixed regional performance.
- Titleist golf equipment grew 5% both quarterly and year-to-date, driven by Pro V1 franchise strength and successful launches of T-Series irons and limited edition wedges.
- +13 more takeaways
Smith Douglas Homes Q3 2025 Earnings Call - Navigating Soft Demand with Discipline and Incentives
Smith Douglas Homes reported third quarter 2025 earnings with $17.2 million pre-tax income and a 21% gross margin amidst a soft housing market. While home closings dipped slightly year-over-year, net ...
- Smith Douglas Homes generated $17.2 million in pre-tax income and $0.24 earnings per share for Q3 2025.
- Home sales revenue was $262 million on 788 closings, down 3% year-over-year, with an average selling price of $333,000.
- Gross margins narrowed to 21% from 26.5% last year due to higher lot costs (27.8% of revenue) and increased incentives.
- +17 more takeaways
InMode 3Q 2025 Earnings Call - Global Expansion and Product Pipeline Offset Margin Pressure
InMode reported Q3 2025 revenues of $93.2 million, reflecting a challenging year-over-year comparison due to a high base with pre-order sales last year, yet managed solid growth in consumables especia...
- Q3 2025 revenue was $93.2 million, down from $130.2 million in Q3 2024, reflecting tough comps with $31.9 million pre-orders last year.
- Consumables and services grew 26% year-over-year to $19.9 million, driven by international markets.
- Minimally invasive platforms represented 75% of total revenues.
- +12 more takeaways
Frontdoor 3Q 2025 Earnings Call - Margin Gains and HVAC Growth Propel Record Outlook
Frontdoor delivered a robust third quarter in 2025, posting 14% revenue growth to $618 million, and driving net income up 5% to $106 million. Operational excellence, especially through disciplined pri...
- Revenue rose 14% year-over-year to $618 million in Q3 2025.
- Gross profit margin improved by 60 basis points to 57%.
- Net income increased 5% to $106 million; adjusted EBITDA grew 18% to $195 million.
- +13 more takeaways
Turning Point Brands Q3 2025 Earnings Call - White Nicotine Pouch Sales Surge 628% Driving Raised Full-Year Guidance
Turning Point Brands delivered a robust Q3 2025 performance, with consolidated revenue climbing 31% to $119 million and a 17% rise in adjusted EBITDA to $31.3 million. Modern oral nicotine pouches, es...
- Q3 revenue rose 31% to $119 million, beating expectations.
- Adjusted EBITDA increased 17% to $31.3 million with 26.3% margin.
- Modern oral nicotine pouch sales (Fre and On!) jumped 628% YoY to $36.7 million, now 31% of revenue.
- +12 more takeaways
QVC Group Q3 2025 Earnings Call - Social and Streaming Growth Temper Declines Amid TV Viewership Drop
QVC Group delivered a mixed third quarter in 2025 as ongoing declines in traditional linear TV viewership pressured revenue across its core segments, with total company revenue down 6% in constant cur...
- Q3 total revenue declined 6% in constant currency, pressured by lower linear TV viewership and macroeconomic challenges.
- QXH revenue fell 7%, QVC International declined 5%, and Cornerstone revenue dropped 8% year over year.
- Social and streaming platforms within QXH revenue grew approximately 30% year over year, now representing low double-digit percentages of revenue.
- +10 more takeaways